Xenon Pharmaceuticals (XENE) EBITDA (2013 - 2026)

Xenon Pharmaceuticals (XENE) has reported EBITDA for 14 consecutive years, with -$112.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 54.43% year-over-year to -$112.3 million; the TTM figure through Mar 2026 stood at -$412.7 million (down 40.84% YoY), while the FY2025 annual figure was -$373.1 million, down 33.57% from the prior year.
• EBITDA declined to -$112.3 million in Q1 2026 per XENE's latest filing, from -$109.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$17.4 million in Q1 2022 and bottomed at -$112.3 million in Q1 2026.
• Historically, EBITDA has averaged -$65.2 million across 5 years, with a median of -$59.0 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA declined 8.16% — and 2023, when it slumped 182.41%.
• Xenon Pharmaceuticals' EBITDA stood at -$43.3 million in 2022, then decreased by 23.92% to -$53.7 million in 2023, then tumbled by 44.29% to -$77.5 million in 2024, then tumbled by 41.68% to -$109.8 million in 2025, then declined by 2.33% to -$112.3 million in 2026.
• Business Quant data shows XENE's EBITDA at -$112.3 million in Q1 2026, -$109.8 million in Q4 2025, and -$96.3 million in Q3 2025.